

European Life Sciences

European life sciences real estate strategy offering attractive risk-adjusted returns, underpinned by a robust pipeline of development opportunities in a thematic and high growth sector.

What is life sciences?

The life sciences industry is comprised of companies involved in the research, development and manufacture of pharmaceuticals, therapies and medical devices, which help to foster medical innovations with the aim of extending the length and quality of human life.

Real estate has a key role to play in the growth and expansion of the sector by developing buildings which are purpose built for life science companies. These companies are tied to locations due to infrastructure, skilled staff requirements, access to universities and manufacturing facilities. This represents a compelling opportunity to form long-term arrangements for real estate requirements.

What is the investment strategy?

- Development led approach focused on dedicated life sciences facilities broadly diversified across Europe focusing on wet lab and manufacturing facilities.
- Following on from our secured UK portfolio, with a forecasted gross development value of GBP 3bn, we are now targeting well-located schemes in Europe with the ability to form *clusters* of facilities enabled by skilled staff, high academic quality, and infrastructure.
- Emphasis on delivering best-in-class life sciences facilities / clusters with a strong focus on high specification space such as good manufacturing process (GMP)
- Targeting 15%+ returns¹, net of fees (pre-tax).



Why Life Sciences in Europe?

High growth sector: growth in amount of capital raised for life sciences companies, could increase occupier demand for appropriate research & development, and manufacturing real estate.

Fundamental undersupply: fundamental demand/supply imbalance due to limited fit-for purpose existing stock represents a compelling opportunity given projected future growth of the European life sciences market.

Defensive against COVID-19 structural changes: shift to working from home to have a limited impact on life sciences occupiers vs. other real estate sectors.

Nascent asset class in Europe with few providers: attractive entry point to develop stock and potential for strong rental growth as occupational demand is set to outweigh supply for the foreseeable future.


Europe is an established manufacturing hub for global pharmaceutical products, with academic talent and a skilled workforce, with a supportive tax and policy framework in some markets.

What is the sustainability approach?

Social value benefits: medical breakthroughs which lead to new treatments and therapies can offer significant societal benefits by enhancing and extending human life. Real estate has a key role to play to help facilitate the growth and expansion of the sector, e.g. creating job opportunities.

Environmental: commitment to high sustainability credentials throughout the build. We will analyze the carbon lifecycle to try to mitigate carbon emissions during the construction phase, with a high level of operational efficiency once built.

Governance: UBS' Real Estate & Private Markets EPM has a strong sustainability and governance track record including consistent GRESB results.



What is the strategy's edge?

Unique integrated investment platform

Collaboration of 3 life sciences sector specialists: UBS Asset Management (UBS-AM), UBS Investment Bank (UBS IB) and our Development Partnerships.

UBS-AM Life Sciences Real Estate Team

- Established senior investment team supported by additional research & strategy professionals, ESG & sustainability specialists, investment specialists and the broader corporate functional teams within the Real Estate & Private Markets business.
- To date, the team has purchased sites in the UK's Golden Triangle with a forecasted gross development value of GBP 3bn, having already developed out its first GMP facility.

UBS Investment Bank

- Technical expertise / knowledge on life sciences occupiers.
- Largest bookrunner of healthcare IPOs globally (2018-2023 YTD) and largest healthcare M&A advisory business in EMEA (2019-2023 YTD)².
- Extensive research capabilities: UBS was named Institutional Investor's top global equity research firm for three consecutive years from 2019-21, coming 2nd in 2022³.

Development Partnerships

- In the UK, our established partnership with Reef Group, who have a strong track record coupled expertise in the life sciences sector, helps to differentiate our strategy.
- We are working with Reef across our European platform, ensuring consistency and quality of design, whilst also partnering with local specialist developers to ensure delivery.

Differentiated pipeline building on UK progress Having purchased a portfolio of assets in the UK's Golden Triangle, with a forecasted gross development value of GBP 3 bn, we've demonstrated our ability to identify and secure life sciences development projects.

Our European pipeline of opportunities is continuing to be progressed with sites in focus to the right and an overall pipeline summary can be found below:

- Number of sites: 8
- Total area: ca. 5.7 m sqft / 530k sqm
- Total forecasted GDV (excl. UK exposure): EUR 2.6 bn+



Indicative details⁴

Target investments	 Development-led approach, targeting projects across Europe; with a focus on high specification space such as Good Manufacturing Practice (GMP) facilities and wet labs Markets for consideration includes UK, Netherlands, Germany, France, Belgium, Switzerland and Nordics Exposure to the UK will be via UBS' UK life sciences portfolio
Target return	– Portfolio level (pre-tax): 15%+ (net) ¹
Target debt	– ca. 55% leverage at portfolio level
Equity required	– ca. EUR 1,000m
Pipeline	 Having secured a portfolio in the UK, the team is now building out a pipeline of European opportunities
Asset criteria	 Well-located in established clusters enabled by skilled staff, high academic quality, and infrastructure

Source: UBS Asset Management, Real Estate & Private Markets (REPM), August 2023. **1** Target returns presented herein do not constitute a forecast of future returns. There is no assurance that the strategy will achieve its target performance; **2** UBS Investment Bank, Dealogic, August 2023; **3** Institutional Investor, January 2022; **4** This does not constitute a guarantee by UBS AG, Asset Management.

For professional / qualified investors For market sounding purposes November 2023

For more information, please contact:

Nick Clare

Capability Specialist Real Estate Europe ex DACH +44-207-901 54 22 nicholas.clare@ubs.com

Olivia Drew

Portfolio Manager European Life Sciences +44 -207-567 74 15 olivia.drew@ubs.com

For marketing and information purposes by UBS. For professional/qualified/accredited/institutional investors only. To be used for generic or sounding purposes.

This document and its contents have not been reviewed by, delivered to or registered with any regulatory or other relevant authority in any jurisdiction. This document is for informational purposes and should not be construed as an offer or invitation to the public, direct or indirect, to buy or sell securities. This document is intended for limited distribution and only to the extent permitted under applicable laws in any jurisdiction. No representations are made with respect to the eligibility of any recipients of this document to acquire interests in securities under the laws of any jurisdiction.

Before investing in a product please read the latest prospectus and key investor information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. This document is for professional clients / qualified investors only. This document is not to be distributed to or relied upon by Retail Clients under any circumstances. Using, copying, reproducing, redistributing or republishing any part of this publication without the written permission of UBS-AM is prohibited. The recipient agrees that this information shall remain strictly confidential where it relates to the Investment Manager's business. The prior consent of UBS-AM should be obtained prior to the disclosure of commercially sensitive information to a third party (excluding the professional advisors of the recipient). The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and are a reflection of UBS-AM's best judgment at the time this report is compiled. No responsibility is accepted for any errors or omissions and all such information and opinions are subject to change without notice; we are under no obligation to update or alter forward-looking statements or opinions as a result of new information. The views expressed in this document are solely the views of UBS-AM and may not necessarily reflect the views of other parts of the UBS Group. These views are subject to change without notice. This information is being provided for information purposes only and does not constitute advice or a recommendation as to whether to make an investment and is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. This document is for distribution only under such circumstances as may be permitted by applicable law. It was written without reference to any specific or future investment objective, financial or tax situation or requirement on the part of a particular individual or group. This information is not intended to provide, and should not be relied upon for, accounting, legal or tax advice, or investment recommendations. You should consult your tax, legal, accounting or other specialist advisors as to the legal and tax implications of investing. UBS-AM, its related companies, or its clients may, from time to time, invest in or divest of interests in the funds referred to in this material. All such information and opinions are subject to change without notice. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. Please note that past performance is not a guide to the future, that the value of investments and the income from them may go down as well as up and that investors may not get back the original amount invested. With Investment in real assets, the underlying assets are very illiquid. In certain circumstances, repatriations might be delayed if an investment is not readily saleable and there is insufficient cash within the portfolio. The value of investments and the income from them may go down as well as up, and investors may not get back the original amount invested. A summary of investor rights in English can be found online at: ubs.com/funds. More explanations of financial terms can be found at ubs.com/glossary.

Source for all data and charts (if not indicated otherwise): UBS Asset Management or one of the Fund's portfolio companies. Telephone calls may be recorded. © UBS 2023. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

